Clinico-pathological characteristics of IGFR1 and VEGF-A co-expression in early and locally advanced-stage lung adenocarcinoma
CONCLUSIONS: These results suggest that IGFR1+&VEGF-A+ is expected to be a disadvantageous factor for prognosis in the subgroup of EGFR mutation in patients with early and locally advanced-stage lung adenocarcinoma. What's more, this study may provide the theoretical possibility to screen optimal population for a combination therapy with anti-VEGF and anti-IGFR1 in patients with early and locally advanced-stage lung adenocarcinoma.PMID:37702808 | DOI:10.1007/s00432-023-05371-0
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Wenting Liu Junling Xia Qingwu Du Jingya Wang Ting Mei Tingting Qin Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Immunotherapy | Insulin | Lung Cancer | Study